4.8 Article

Poly(ADP-Ribose) Polymerase Is Hyperactivated in Homologous Recombination-Defective Cells

期刊

CANCER RESEARCH
卷 70, 期 13, 页码 5389-5398

出版社

AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-09-4716

关键词

-

类别

资金

  1. Swedish Cancer Society
  2. Swedish Children's Cancer Foundation
  3. Swedish Research Council
  4. Swedish Pain Relief Foundation
  5. Yorkshire Cancer Research
  6. Cancer Research UK
  7. Medical Research Council
  8. Cancer Research UK [8971] Funding Source: researchfish
  9. Medical Research Council [G0700730] Funding Source: researchfish
  10. MRC [G0700730] Funding Source: UKRI

向作者/读者索取更多资源

Poly(ADP-ribose) (PAR) polymerase 1 (PARP1) is activated by DNA single-strand breaks (SSB) or at stalled replication forks to facilitate DNA repair. Inhibitors of PARP efficiently kill breast, ovarian, or prostate tumors in patients carrying hereditary mutations in the homologous recombination (HR) genes BRCA1 or BRCA2 through synthetic lethality. Here, we surprisingly show that PARP1 is hyperactivated in replicating BRCA2-defective cells. PARP1 hyperactivation is explained by the defect in HR as shRNA depletion of RAD54, RAD52, BLM, WRN, and XRCC3 proteins, which we here show are all essential for efficient HR and also caused PARP hyperactivation and correlated with an increased sensitivity to PARP inhibitors. BRCA2-defective cells were not found to have increased levels of SSBs, and PAR polymers formed in HR-defective cells do not colocalize to replication protein A or gamma H2AX, excluding the possibility that PARP hyperactivity is due to increased SSB repair or PARP induced at damaged replication forks. Resistance to PARP inhibitors can occur through genetic reversion in the BRCA2 gene. Here, we report that PARP inhibitor-resistant BRCA2-mutant cells revert back to normal levels of PARP activity. We speculate that the reason for the sensitivity of HR-defective cells to PARP inhibitors is related to the hyperactivated PARP1 in these cells. Furthermore, the presence of PAR polymers can be used to identify HR-defective cells that are sensitive to PARP inhibitors, which may be potential biomarkers. Cancer Res; 70(13); 5389-98. (C) 2010 AACR.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.8
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据